{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:21:53Z","timestamp":1792797713036,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jconrel.2023.07.045","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T06:51:26Z","timestamp":1691995886000},"page":"470-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia"],"prefix":"10.1016","volume":"361","author":[{"given":"James M.","family":"Kelvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison L.","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn K.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle M.","family":"Humber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travon A.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey A.","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Qui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashis","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan T.","family":"Jui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbur A.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas K.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"DeRyckere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik C.","family":"Dreaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.07.045_bb0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V26.5.642.642","article-title":"The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia","volume":"26","author":"Frei","year":"1965","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0010","first-page":"1258","article-title":"Intensive combination chemotherapy and X-irradiation in Hodgkin\u2019s disease","volume":"27","author":"Moxley","year":"1967","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50036","article-title":"A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity","volume":"8","author":"Palmer","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0025","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/jps.21620","article-title":"Pharmacokinetics of CPX-351 (cytarabine\/daunorubicin HCl) liposome injection in the mouse","volume":"98","author":"Bayne","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-60761-416-6_13","article-title":"Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention","volume":"596","author":"Harasym","year":"2010","journal-title":"Methods Mol. Biol. (Clifton, N.J.)"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0035","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/msb.2011.71","article-title":"Systematic exploration of synergistic drug pairs","volume":"7","author":"Cokol","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0045","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1073\/pnas.1337088100","article-title":"Systematic discovery of multicomponent therapeutics","volume":"100","author":"Borisy","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/acs.molpharmaceut.7b00843","article-title":"Ratio-dependent synergism of a doxorubicin and Olaparib combination in 2D and spheroid models of ovarian cancer","volume":"15","author":"Eetezadi","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0055","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1021\/acs.molpharmaceut.8b00246","article-title":"BRCA status does not predict synergism of a carboplatin and Olaparib combination in high-grade serous ovarian cancer cell lines","volume":"15","author":"Shen","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0060","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1021\/nn405674m","article-title":"Nanoparticles for combination drug therapy","volume":"7","author":"Ma","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0065","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature03794","article-title":"Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system","volume":"436","author":"Sengupta","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0070","doi-asserted-by":"crossref","first-page":"ra44","DOI":"10.1126\/scisignal.2005261","article-title":"A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways","volume":"7","author":"Morton","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0075","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1158\/1078-0432.CCR-15-0013","article-title":"Tumor-targeted synergistic blockade of MAPK and PI3K from a layer-by-layer nanoparticle","volume":"21","author":"Dreaden","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0080","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/cancers11060752","article-title":"In vivo evaluation of dual-targeted nanoparticles encapsulating paclitaxel and everolimus","volume":"11","author":"Houdaihed","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0085","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1021\/acsnano.6b00320","article-title":"Rationally designed 2-in-1 nanoparticles can overcome adaptive resistance in cancer","volume":"10","author":"Goldman","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062630","article-title":"Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: a comparison of docetaxel-loaded block copolymer micelles and Taxotere\u00ae","volume":"8","author":"Mikhail","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0095","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acscombsci.0c00081","article-title":"Rapid assembly and screening of multivalent immune cell-redirecting therapies for leukemia","volume":"22","author":"Do","year":"2020","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0100","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1038\/s41467-020-17958-z","article-title":"Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints","volume":"11","author":"Kong","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0105","doi-asserted-by":"crossref","first-page":"1900018","DOI":"10.1002\/adfm.201900018","article-title":"Binary targeting of siRNA to hematologic cancer cells in vivo using layer-by-layer nanoparticles","volume":"29","author":"Choi","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0110","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1021\/nn4047925","article-title":"Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment","volume":"7","author":"Deng","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","article-title":"CPX-351 (vyxeos) in AML","volume":"61","author":"Alfayez","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/bloodadvances.2021006139","article-title":"CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies","volume":"6","author":"Hu","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0130","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0135","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2016.34.15_suppl.7000","article-title":"Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML","volume":"34","author":"Lancet","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0140","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1038\/bcj.2012.46","article-title":"Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia","volume":"3","author":"Brandao","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0145","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1038\/sj.onc.1209633","article-title":"Lymphoblastic leukemia\/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase","volume":"25","author":"Keating","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0150","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1038\/onc.2013.40","article-title":"Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia","volume":"32","author":"Lee-Sherick","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0155","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2013-01-478156","article-title":"Mer receptor tyrosine kinase is a therapeutic target in pre\u2013B-cell acute lymphoblastic leukemia","volume":"122","author":"Linger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0165","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1078-0432.CCR-16-1330","article-title":"UNC2025, a MERTK small-molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models","volume":"23","author":"DeRyckere","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85630","article-title":"The MERTK\/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia","volume":"1","author":"Minson","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0175","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1021\/jm500749d","article-title":"UNC2025, a potent and orally bioavailable MER\/FLT3 dual inhibitor","volume":"57","author":"Zhang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0180","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1073\/pnas.0609370104","article-title":"High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0185","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.chembiol.2010.06.008","article-title":"Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity","volume":"17","author":"Farha","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01384","article-title":"Additive dose response models: defining synergy","volume":"10","author":"Lederer","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0195","doi-asserted-by":"crossref","first-page":"12254","DOI":"10.1073\/pnas.1201281109","article-title":"Mechanism-independent method for predicting response to multidrug combinations in bacteria","volume":"109","author":"Wood","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0200","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","article-title":"T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies","volume":"2","author":"Cordo","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0210","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(15)00254-9","article-title":"Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis","volume":"3","author":"Conter","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0220","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOH.0b013e3283623c61","article-title":"Early T-cell precursor acute lymphoblastic leukaemia","volume":"20","author":"Haydu","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0225","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V114.22.9.9","article-title":"Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction\u2014a children\u2019s oncology group (COG) study","volume":"114","author":"Wood","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0235","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.addr.2017.06.010","article-title":"Drug discovery and therapeutic delivery for the treatment of B and T cell tumors","volume":"114","author":"Stephenson","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0240","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood-2021-151726","article-title":"Therapeutic targeting of Mertk and BCL-2 in T-cell and early T-precursor acute lymphoblastic leukemia","volume":"138","author":"Summers","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053190","article-title":"FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors","volume":"8","author":"Neumann","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0250","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107577","article-title":"MERTK in cancer therapy: targeting the receptor tyrosine kinase in tumor cells and the immune system","volume":"213","author":"Huelse","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0260","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1038\/onc.2012.355","article-title":"Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer","volume":"32","author":"Linger","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4161\/cbt.7.1.5128","article-title":"Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin\u2019s lymphoma cells","volume":"7","author":"Li","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0270","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0275","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.celrep.2019.03.045","article-title":"High-complexity shRNA libraries and PI3 kinase inhibition in cancer: high-fidelity synthetic lethality predictions","volume":"27","author":"Mues","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0280","doi-asserted-by":"crossref","first-page":"2000297","DOI":"10.1002\/ejlt.202000297","article-title":"The use of phospholipids to make pharmaceutical form line extensions","volume":"123","author":"van Hoogevest","year":"2021","journal-title":"Eur. J. Lipid Sci. Technol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0290","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0167-7799(91)90088-Y","article-title":"pH gradients and membrane transport in liposomal systems","volume":"9","author":"Cullis","year":"1991","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053964","article-title":"MERTK interactions with SH2-domain proteins in the retinal pigment epithelium","volume":"8","author":"Shelby","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0300","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1021\/acs.chemmater.7b01979","article-title":"Nanoparticle surface functionality dictates cellular and systemic toxicity","volume":"29","author":"Saei","year":"2017","journal-title":"Chem. Mater."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0305","doi-asserted-by":"crossref","first-page":"E5859","DOI":"10.1073\/pnas.1805358115","article-title":"Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters","volume":"115","author":"McKinlay","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0310","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41565-022-01310-1","article-title":"Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma","volume":"18","author":"Detappe","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0315","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0325","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0330","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1101\/gr.121095.111","article-title":"Synthetic spike-in standards for RNA-seq experiments","volume":"21","author":"Jiang","year":"2011","journal-title":"Genome Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0335","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST: a new generation of protein database search programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0340","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/nar\/gkp1137","article-title":"The sanger FASTQ file format for sequences with quality scores, and the Solexa\/Illumina FASTQ variants","volume":"38","author":"Cock","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0345","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/bib\/bbs046","article-title":"A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis","volume":"14","author":"Dillies","year":"2013","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0350","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nmeth.1230","article-title":"Alta-cyclic: a self-optimizing base caller for next-generation sequencing","volume":"5","author":"Erlich","year":"2008","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0355","doi-asserted-by":"crossref","first-page":"D279","DOI":"10.1093\/nar\/gkv1344","article-title":"The Pfam protein families database: towards a more sustainable future","volume":"44","author":"Finn","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0360","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0365","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0370","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nbt.1621","article-title":"Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation","volume":"28","author":"Trapnell","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0375","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nmeth.1226","article-title":"Mapping and quantifying mammalian transcriptomes by RNA-Seq","volume":"5","author":"Mortazavi","year":"2008","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0380","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics J. Integr. Biol."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0385","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0390","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ. Psychol. Meas."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0395","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1021\/js960177k","article-title":"Prediction of distribution coefficient from structure. 1. Estimation method","volume":"86","author":"Csizmadia","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0400","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/ci00020a009","article-title":"Computer automated log P calculations based on an extended group contribution approach","volume":"34","author":"Klopman","year":"1994","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0405","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1021\/ci00063a006","volume":"29","author":"Viswanadhan","year":"1989","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.jconrel.2023.07.045_bb0410","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/leu.2017.136","article-title":"JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias","volume":"31","author":"Delgado-Martin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0415","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2008-02-138172","article-title":"NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity","volume":"113","author":"Armstrong","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0420","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/leu.2012.337","article-title":"Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts","volume":"27","author":"Yost","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2023.07.045_bb0425","doi-asserted-by":"crossref","DOI":"10.3791\/50720-v","article-title":"Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia","author":"Christoph","year":"2013","journal-title":"J. Vis. Exp.: JoVE"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:51:44Z","timestamp":1759164704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923004698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":85,"alternative-id":["S0168365923004698"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.045","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}